Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences (Nasdaq: WVE) announced that its CEO, Paul Bolno, will participate in an analyst-led fireside chat at the 2022 Jefferies Healthcare Conference in New York City on June 8, 2022, at 3:00 p.m. ET. A live webcast will be available on Wave's Investor Relations page, with a replay accessible for a limited time after the event. Wave Life Sciences is focused on developing genetic medicines for serious diseases using its proprietary PRISM platform.
Wave Life Sciences (WVE) announced first clinical data from the FOCUS-C9 trial, showcasing effective target engagement of WVE-004 for C9-ALS and C9-FTD. The company reported a net loss of $37.8 million for Q1 2022, with revenues of $1.8 million, primarily from a collaboration with Takeda. R&D expenses decreased to $27.5 million, while G&A expenses rose to $12.4 million. Wave has $111.7 million in cash as of March 31, 2022, sufficient to fund operations into Q2 2023. Key clinical data updates are anticipated later this year for Huntington’s disease and Duchenne muscular dystrophy.
Wave Life Sciences (Nasdaq: WVE), a clinical-stage genetic medicines company, announced that Paul Bolno, MD, CEO, will participate in two investor conferences in May 2022. The first is at the RBC Capital Markets 2022 Global Healthcare Conference on May 17, 2022, from 2:05 p.m. to 2:30 p.m. ET in New York. The second is at the H.C. Wainwright Global Investment Conference on May 24, 2022, from 3:30 p.m. to 4:00 p.m. ET in Miami. Live webcasts will be available on their Investor Relations page.
Wave Life Sciences Ltd. (Nasdaq: WVE) has announced a live webcast and conference call scheduled for May 12, 2022, at 8:30 a.m. ET to discuss its first quarter 2022 financial results and provide a business update. The event will be accessible via the company's investor relations website, with teleconference options available for domestic and international participants. Wave Life Sciences focuses on developing life-changing genetic medicines using its proprietary PRISM platform to target genetically defined diseases.
Wave Life Sciences announced the publication of preclinical data for WVE-004, targeting C9orf72-associated ALS and frontotemporal dementia. The study, published in Molecular Therapy Nucleic Acids, demonstrated significant reductions in pathogenic RNA transcripts and poly(GP) proteins over six months in mice, highlighting its potential efficacy. Initial clinical data from the ongoing FOCUS-C9 trial suggests that these preclinical results are translating into human applications, with effective target engagement and sustained reductions in poly(GP) levels.
Wave Life Sciences Ltd. (Nasdaq: WVE) will participate in Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit on April 26, 2022, at 2:30 p.m. ET. CEO Paul Bolno and SVP Sri Vaddeboina will join an analyst-led fireside chat, which will be streamed live on their Investor Relations page. Wave Life Sciences focuses on delivering innovative genetic medicines for devastating diseases using its PRISM platform for the precise design and production of stereopure oligonucleotides. A replay will be available shortly after the event on their website.
Wave Life Sciences (Nasdaq: WVE) announced positive updates from its Phase 1b/2a FOCUS-C9 trial for WVE-004, targeting C9orf72-associated ALS and frontotemporal dementia. Key findings include significant reductions in poly(GP) levels indicating target engagement, with a 34% decrease observed post a 30 mg single dose. The dosing observation period will now extend to six months to assess maximum poly(GP) reduction. Multidose cohorts at 10 mg are underway, with further data expected throughout 2022, reinforcing the trial’s adaptive design and the potential of its proprietary PN chemistry.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced that CEO Paul Bolno will participate in a virtual fireside chat at the Stifel 2022 CNS Days event on March 28, 2022, at 9:15 a.m. EDT. This event highlights Wave's commitment to developing genetic medicines aimed at treating severe diseases. A live webcast of the presentation will be available on the Investor Relations page of Wave's website, with a replay available for a limited time after the event.
Wave Life Sciences Ltd. (Nasdaq: WVE) announced key presentations at the OPT Congress and RNA Editing Summit, showcasing advancements in their A-to-I(G) RNA base editing oligonucleotides (AIMers). Highlights include preclinical data on their AIMer program for Alpha-1 antitrypsin deficiency (AATD), demonstrating editing efficiency and protein restoration over 19 weeks. The AIMers leverage the body's natural ADAR enzymes for precise editing without permanent genomic changes. The company's IND-enabling studies are slated for Q3 2022, emphasizing Wave's commitment to innovative genetic therapies.
Wave Life Sciences (Nasdaq: WVE) announced preclinical proof-of-concept data demonstrating the efficacy of its AIMer technology for RNA base editing in non-human primates. Published in Nature Biotechnology, the study reported up to 50% editing of the ACTB transcript in the liver, with levels persisting at 40% for over a month. AIMers simplify delivery without the need for exogenous enzymes, potentially enhancing therapeutic applications, especially for genetic conditions like alpha-1 antitrypsin deficiency.